Showing results (81-90 of 244) with videos related to
Sort By:
Pageof 25
Lab on a Chip|July 12, 2024
Deformation under flow and morphological recovery of cancer cellsEmile Gasser, Emilie Su, Kotryna Vaidžiulytė, et al.International Journal of Radiation Oncology, Biology, Physics|June 17, 2025
Cardiac Outcomes Following Adjuvant Radiation Therapy in Triple-Negative Breast Cancer Patients With Prior Autoimmune MyocarditisPierre Loap, Assile El Fakih, Clara Helal, et al.Bulletin Du Cancer|June 10, 2017
[Internal quality control on HER2 status determination in breast cancers: Experience of a cancer center]Carine Ngo, Marick Laé, Julia Ratour, et al.American Journal of Clinical Oncology|June 19, 2012
Prospective and comparative evaluation of the toxicity of adjuvant concurrent chemoradiotherapy after neoadjuvant chemotherapy for breast cancerVirginie Marchand, Antoine Angelergues, Vanessa Gobaux, et al.Cancers|May 14, 2022
Oral Etoposide and Trastuzumab Use for HER2-Positive Metastatic Breast Cancer: A Retrospective Study from the Institut Curie HospitalsClelia Chalumeau, Matthieu Carton, Alexandre Eeckhoutte, et al.The Lancet. Oncology|October 3, 2014
Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trialJoseph Gligorov, Dinesh Doval, José Bines, et al.Breast (Edinburgh, Scotland)|July 23, 2014
A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trialAntonio Llombart-Cussac, Xavier Pivot, Laura Biganzoli, et al.International Journal of Radiation Oncology, Biology, Physics|May 19, 2010
Management of inflammatory breast cancer after neoadjuvant chemotherapySoumya Abrous-Anane, Alexia Savignoni, Caroline Daveau, et al.Cancers|January 27, 2021
HER2-Positive Breast Cancer Patients with Pre-Treatment Axillary Involvement or Postmenopausal Status Benefit from Neoadjuvant Rather than Adjuvant Chemotherapy Plus Trastuzumab RegimensEnora Laas, Arnaud Bresset, Jean-Guillaume Féron, et al.Current Clinical Pharmacology|November 16, 2011
Unexpected high levels of vorinostat when combined with vinorelbine in patients with advanced cancerPeggy Gandia, Cecile Arellano, Quentin Chalret du Rieu, et al.Pageof 25